A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Latest Information Update: 29 Jan 2025
At a glance
- Drugs BMS 813160 (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 Aug 2024 Status changed from active, no longer recruiting to completed.
- 10 Nov 2022 Planned End Date changed from 28 Oct 2024 to 14 Oct 2024.
- 03 Mar 2022 Planned End Date changed from 31 Jan 2025 to 28 Oct 2024.